News Alert: Calif. 340B Health Centers Ask Judge to Stop Tomorrow’s “Devastating” State Medicaid Drug Payment Changes

California health centers asked U.S. District Judge John A. Mendez yesterday to stop a state Medicaid drug reimbursement change due to begin tomorrow that they say would strip away all their 340B drug discount savings.

California health centers asked a federal district judge yesterday to stop a major state Medicaid drug reimbursement change due to begin tomorrow.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Manchin’s Idea that VA Negotiate Medicare Drug Prices Could Adversely Impact 340B Program, Expert Suggests

Congress should let the VA negotiate drug prices on behalf of Medicare, U.S. Sen. Joe Manchin (W.Va.) reportedly told the Senate Democratic Caucus this week.

U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.

Read More »

Cloudmed Acquires 340B Technology Company par8o

par8o, which provides 340B services including a platform to help 340B covered entities manage their patient referral claims, has been acquired by Cloudmed.

Boston-based par8o, which provides 340B services including a platform to help 340B covered entities manage their patient referral claims, has been acquired by Cloudmed.

Please Login or Become a Paid Subscriber to View this Content

Read More »

House Committee Releases Report With 340B Implications

The U.S. House Oversight and Reform Committee has issued a blistering report about drug industry pricing and business practices.

The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.

Please Login or Become a Paid

Read More »

Calif. Health Centers Will Ask Court to Stop State Medicaid Change That Could Reduce 340B Savings Significantly

California health centers plan to seek a court order stopping the state from moving Medicaid managed care drug benefits to Medicaid fee for service on Jan. 1.

As California’s Medicaid program moves toward implementing a fee-for-service payment structure for drug coverage, one of the primary foes of the transition has returned to court to obtain a temporary restraining order.

Please Login or Become

Read More »

Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders

The U.S. Supreme Court heard a case this week about the Medicare disproportionate share (DSH) adjustment percentage calculation—a 340B eligibility criterion for hospitals.

340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.

Please Login or Become

Read More »

340B Report Publisher and CEO: Expect Congress to Act on 340B Contract Pharmacy Before Midterm Elections

Expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in

Read More »

Drug Pricing Watchdog Identifies Most Significant Price Hikes

AbbVie’s anti-inflammatory blockbuster Humira accounted for nearly $1.4 billion in additional unsupported U.S. drug spending last year, the Institute for Clinical and Economic Review says.

Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.

Read More »

AHA Criticizes JAMA Study of What Hospitals Charge for Clinician-Administered Drugs

The AHA says a JAMA study on what hospitals charge insurers for clinician-administered drugs lacks context.

The American Hospital Association (AHA) has pushed back on a JAMA Internal Medicine study suggesting that leading acute care facilities that are 340B covered entities have wide variations in how much they charge insurers for clinician-administered drugs.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report